Ketamine papers & reference material

Please click on titles for full excerpt


Acevedo-Diaz EE, Cavanaugh GW, Greenstein D, et al. Comprehensive assessment of side effects associated with a single dose of ketamine in treatment-resistant depression. Journal of affective disorders. 2020;263:568-575. doi:10.1016/j.jad.2019.11.028


Andrade C. Ketamine for Depression, 4: In What Dose, at What Rate, by What Route, for How Long, and at What Frequency? The Journal of clinical psychiatry. 2017;78(7):e852-e857. doi:10.4088/JCP.17f11738


Andrade C. Oral Ketamine for Depression, 2: Practical Considerations. The Journal of clinical psychiatry. 2019;80(2). doi:10.4088/JCP.19f12838


Andrade C. Oral Ketamine for Depression, 1: Pharmacologic Considerations and Clinical Evidence. The Journal of clinical psychiatry. 2019;80(2). doi:10.4088/JCP.19f12820


Bayes A, Dong V, Loo C. Considerations for use of ketamine to treat depression in Australia and New Zealand. Australian & New Zealand Journal of Psychiatry. 2019;53(11):1117-1120. doi:10.1177/0004867419866510


Bozymski, K. M., Crouse, E. L., Titus-Lay, E. N., Ott, C. A., Nofziger, J. L., & Kirkwood, C. K. (2020). Esketamine: A Novel Option for Treatment-Resistant Depression. The Annals of Pharmacotherapy, 54(6), 567–576. https://doi.org/10.1177/1060028019892644

Bratsos S, Saleh SN. Clinical Efficacy of Ketamine for Treatment-resistant Depression. Cureus. 2019;11(7):e5189. doi:10.7759/cureus.5189


Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study. (English) By: Correia-Melo FS; Leal GC; Vieira F; Jesus-Nunes AP; Mello RP; Magnavita G; Caliman-Fontes AT; Echegaray MVF; Bandeira ID; Silva SS; Cavalcanti DE; Araújo-de-Freitas L; Sarin LM; Tuena MA; Nakahira C; Sampaio AS; Del-Porto JA; Turecki G; Loo C; Lacerda ALT; Quarantini LC, Journal of affective disorders [J Affect Disord], ISSN: 1573-2517, 2020 Mar 01; Vol. 264, pp. 527-534; Publisher: Elsevier/North-Holland Biomedical Press; PMID: 31786030;


De Gioannis A, De Leo D. Oral ketamine augmentation for chronic suicidality in treatment-resistant depression. Australian & New Zealand Journal of Psychiatry. 2014;48(7):686. doi:10.1177/0004867414520754.


Domany Y, Bleich-Cohen M, Tarrasch R, et al. Repeated oral ketamine for out-patient treatment of resistant depression: randomised, double-blind, placebo-controlled, proof-of-concept study. The British journal of psychiatry : the journal of mental science. 2019;214(1):20-26. doi:10.1192/bjp.2018.196.


Fu, D.-J., Ionescu, D. F., Li, X., Lane, R., Lim, P., Sanacora, G., Hough, D., Manji, H., Drevets, W. C., & Canuso, C. M. (2020). Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). The Journal of Clinical Psychiatry, 81(3). https://doi.org/10.4088/JCP.19m13191

Hartberg J, Garrett-Walcott S, De Gioannis A. Impact of oral ketamine augmentation on hospital admissions in treatment-resistant depression and PTSD: a retrospective study. Psychopharmacology. 2018;235(2):393-398. doi:10.1007/s00213-017-4786-3.


Lascelles, K., Marzano, L., Brand, F., Trueman, H., McShane, R., & Hawton, K. (2019). Effects of ketamine treatment on suicidal ideation: a qualitative study of patients’ accounts following treatment for depression in a UK ketamine clinic. BMJ Open, 9(8), e029108. https://doi.org/10.1136/bmjopen-2019-029108


Lent JK, Arredondo A, Pugh MA, Austin PN. Ketamine and Treatment-Resistant Depression. AANA journal. 2019;87(5):411-419. https://search.ebscohost.com/login.aspx?direct=true&db=mnh&AN=31612847&site=ehost-live


Li KX, Loshak H. Intravenous Ketamine for Adults with Treatment-Resistant Depression or Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines. October 2019. https://search.ebscohost.com/login.aspx?direct=true&db=mdc&AN=31873996&site=ehost-live


Liu G-L, Cui Y-F, Lu C, Zhao P. Ketamine a dissociative anesthetic: Neurobiology and biomolecular exploration in depression. Chemico-biological interactions. 2020;319:109006. doi:10.1016/j.cbi.2020.109006.


Liu W, Zhou Y, Zheng W, et al. Repeated intravenous infusions of ketamine: Neurocognition in patients with anxious and nonanxious treatment-resistant depression. Journal of affective disorders. 2019;259:1-6. doi:10.1016/j.jad.2019.08.012.


Mandal S, Sinha VK, Goyal N. Efficacy of ketamine therapy in the treatment of depression. Indian journal of psychiatry. 2019;61(5):480-485. doi:10.4103/psychiatry.IndianJPsychiatry_484_18.


Phillips JL, Norris S, Talbot J, et al. Single and repeated ketamine infusions for reduction of suicidal ideation in treatment-resistant depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2020;45(4):606-612. doi:10.1038/s41386-019-0570-x


Rosenblat JD, Carvalho AF, Li M, Lee Y, Subramanieapillai M, McIntyre RS. Oral Ketamine for Depression: A Systematic Review. The Journal of clinical psychiatry. 2019;80(3). doi:10.4088/JCP.18r12475


Schoevers RA, Chaves TV, Balukova SM, aan het Rot M, Kortekaas R. Oral ketamine for the treatment of pain and treatment-resistant depression†. The British journal of psychiatry : the journal of mental science. 2016;208(2):108-113. doi:10.1192/bjp.bp.115.165498.


SILBERNER, J. Ketamine should be available for treatment resistant depression, says FDA panel. BMJ (Clinical research ed.), [s. l.], v. 364, p. l858, 2019. DOI 10.1136/bmj.l858. Disponível em: https://search.ebscohost.com/login.aspx?direct=true&db=mnh&AN=30796014&site=ehost-live. Acesso em: 24 abr. 2020

Ketamine should be available for treatment resistant depression, says FDA panel. (English) By: Silberner J, BMJ (Clinical Research Ed.) [BMJ], ISSN: 1756-1833, 2019 Feb 22; Vol. 364, pp. l858; Publisher: British Medical Association; PMID: 30796014


Swainson J, Khullar A. Sublingual Ketamine: An Option for Increasing Accessibility of Ketamine Treatments for Depression? The Journal of clinical psychiatry. 2020;81(1). doi:10.4088/JCP.19lr13146


Swiatek KM, Jordan K, Coffman J. New use for an old drug: oral ketamine for treatment-resistant depression. BMJ case reports. 2016;2016. doi:10.1136/bcr-2016-216088.


Wajs, E., Aluisio, L., Holder, R., Daly, E. J., Lane, R., Lim, P., George, J. E., Morrison, R. L., Sanacora, G., Young, A. H., Kasper, S., Sulaiman, A. H., Li, C.-T., Paik, J.-W., Manji, H., Hough, D., Grunfeld, J., Jeon, H. J., Wilkinson, S. T., … Singh, J. B. (2020). Esketamine Nasal Spray Plus Oral Antidepressant in Patients With Treatment-Resistant Depression: Assessment of Long-Term Safety in a Phase 3, Open-Label Study (SUSTAIN-2). The Journal of Clinical Psychiatry, 81(3). https://doi.org/10.4088/JCP.19m12891


Włodarczyk A, Cubała WJ. Safety and Tolerability of Ketamine Use in Treatment-Resistant Bipolar Depression Patients with Regard to Central Nervous System Symptomatology: Literature Review and Analysis. Medicina (Kaunas, Lithuania). 2020;56(2). doi:10.3390/medicina56020067.